DnaJ heat shock protein family (Hsp40) member C6Genealiases: DJC6 · PARK19
Q-omics provides the consensus-scored DNAJC6 profile across patient tissues and cancer cell-line models. DNAJC6 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, DNAJC6 is differentially expressed in 13, with the highest sampling consensus in KICH. Additionally, DNAJC6 protein abundance shows 20,027 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight UCEC, KICH, and GBM as cancer lineages where DNAJC6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DNAJC6 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DNAJC6 survival associations across molecular data types. DNAJC6 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (4) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DNAJC6 RNA expression–survival associations across cancer types. High DNAJC6 expression shows unfavorable associations in UCEC, LIHC, HNSC, BLCA and CESC, but favorable associations in KIRC. The UCEC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCEC as the clearest survival context for DNAJC6 RNA expression.
This table summarizes DNAJC6 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 4. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for DNAJC6. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DNAJC6 shows lower tumor expression in KICH, KIRC and LUSC and higher tumor expression in HNSC, LIHC and LUAD. The KICH box plot shows higher DNAJC6 RNA expression in normal versus tumor tissue (log2 FC = −1.498, t-test p < 0.001).
This table shows molecular features associated with DNAJC6 in patient tissues and cancer cell lines. In patient samples, DNAJC6 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, DNAJC6 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OESOPHAGUS, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and LARGE_INTESTINE.
